Veterans study aims to crack the code on Hard-to-Treat sleep apnea

NCT ID NCT04118387

Recruiting now Knowledge-focused Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study looks at why central sleep apnea happens and how to treat it better. Researchers will test a combination of a drug (acetazolamide), extra oxygen, and a breathing machine (PAP therapy) in 200 veterans with this condition. The goal is to understand the body's breathing control systems so future treatments can be more effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Acetazolamide plus supplemental oxygen plus positive airway pressure (PAP) therapy
What this could lead to: If successful, this study could point toward more effective combination treatments for central sleep apnea, especially in people with heart failure or those taking opioids.
What could go wrong: This is a small, early-phase mechanistic study focused on measuring breathing responses, not on proving long-term benefit. The treatments may not translate into better outcomes in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ABLE BODIED are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central sleep apnea syndrome sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ABLE BODIED SLEEP DISORDERED BREATHING

Contacts and locations

Locations

John D. Dingell VA Medical Center, Detroit, MI
RECRUITING

Detroit, Michigan, 48201-1916, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.